肝細(xì)胞癌的發(fā)病分子機(jī)制十分復(fù)雜，具有預(yù)后差、死亡率高的特點，并且對其有效的系統(tǒng)的治療方案非常有限。近年來，隨著國家對傳統(tǒng)民族醫(yī)藥發(fā)展的重視，涌現(xiàn)出許多具有較好臨床療效的中藥化合物。其中，天然產(chǎn)物小檗堿包含多種藥理活性并且無明顯毒副作用。最近的研究表明小檗堿可以通過多個方面發(fā)揮預(yù)防和降低肝細(xì)胞癌的作用，包括改善糖脂代謝，作用于線粒體有氧呼吸鏈，調(diào)節(jié)腸道微生態(tài)，作用于microRNAs，以及誘導(dǎo)p53上調(diào)和抑制分化抑制因子-1（Id-1）表達(dá)等。綜述小檗堿通過改善代謝水平抗肝細(xì)胞癌的研究進(jìn)展，為臨床應(yīng)用提供依據(jù)。

Due to the complicated molecular pathogenesis of hepatocellular carcinoma (HCC) with poor prognosis and high mortality, the option of effective systemic treatment of HCC is quite limited. In recent years, with the national attention on the development of traditional national medicine, lots of Chinese medicine compounds with good clinical effects have been found. Berberine as a natural product has multiple pharmacological activities, and has been used in traditional Chinese medicine with no significant side effects. Recent research has demonstrated that berberine has prevention and reduction activity against hepatocellular carcinoma through various pharmacological mechanisms, including the improvement of glucose, lipid metabolism, effect on mitochondrial aerobic respiration chain, regulating intestinal microecology, MicroRNAs, and inducing p53 up-regulation and suppressing Id-1 expression, etc. Research progress on anti-hepatocellular carcinoma of berberine by improving metabolism is reviewed in this paper, in order to provide the basis for clinical application.

國家自然科學(xué)基金創(chuàng)新研究群體項目（81621064）；國家自然科學(xué)基金青年項目（81302823）；中國醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與健康科技創(chuàng)新工程項目（2016-I2M-1-011）